GlobalData on MSN
MSD begins KANDLELIT-007 trial of calderasib for NSCLC
Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.
In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Pharmaceutical Technology on MSN
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree
Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.
Merck (known as MSD outside of the United States and Canada) will complete its $9.2 billion acquisition of Cidara ...
CAMBRIDGE, England--(BUSINESS WIRE)--Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial ...
Merck (known as MSD outside the US) has announced an agreement with the US government to provide key products to patients at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback